Pennsylvania’s seventh Risperdal gynecomastia trial came to a premature end last week, after the judge hearing the case granted the defense a Motion for Nonsuit. Attorneys representing the plaintiff have promised to appeal the decision.

5,000+ Risperdal Lawsuits Pending in Pennsylvania

The case was one of more than 5,000 Risperdal lawsuits pending in the Philadelphia Court of Common Pleas, where product liability claims involving the drug’s alleged side effects have been centralized in a mass tort program.  The Plaintiff claims to have developed gynecomastia (a condition characterized by the growth of female breasts in men and boys) due to treatment with the atypical antipsychotic drug.

Judge Kenneth Powell granted  Johnson & Johnson and its  Janssen Pharmaceutical subsidiary  a Motion for Nonsuit on April 17th, after the companies’ lawyers argued that the Plaintiff had not provided enough evidence to prove his claims. His attorneys quickly indicated that they will pursue an appeal.

“Johnson & Johnson thinks the best way to avoid responsibility in a Risperdal case is to keep it from going to a jury,” one of his lawyers told The Legal Intelligencer via an emailed statement, “We are confident this decision will be overturned on appeal, and we will keep fighting for the Hibbs family until their case is decided by a jury—not by a judge.”

Risperdal Litigation

Risperdal is an atypical antipsychotic used to treat schizophrenia, bipolar disorder and aggression linked to autism in adults and children. Johnson & Johnson disclosed in a recent financial filing that roughly 18,500 Risperdal lawsuits were pending in courts throughout the U.S. Plaintiffs pursuing cases in Philadelphia  claim that  the drug’s makers  concealed data linking Risperdal to excessive male breast growth and failed to provide doctors and patients with adequate warnings regarding this potential side effect.

According to, the Pennsylvania litigation has now convened seven Risperdal gynecomastia trials since February 2017. Four have resulted in verdicts for plaintiffs, with financial damage awards ranging from $70 million to $500,000. Jurors declined to award the plaintiff damages in one case, while another case was dismissed in December in the midst of trial.

Summary judgment was granted to the defense in two other Risperdal lawsuits before trials could get underway. Several cases have also been settled just prior to trial.

Contact an Attorney Today

Bernstein Liebhard LLP is representing plaintiffs in lawsuits involving Risperdal and gynecomastia. To learn more, please contact our office at 877-779-1414.

Published April 25, 2017 by